Nalbuphine may help manage opioid-induced urine retention

September 03, 2018

1. Nalbuphine may help manage opioid-induced urine retention

Abstract: http://annals.org/aim/article/doi/10.7326/L18-0387

URLs go live when the embargo lifts

Nalbuphine may help to manage opioid-induced urine retention. Findings from a brief case report are published in Annals of Internal Medicine.

Urine retention is common in the hospital setting and is sometimes caused by the use of opioids. Once opioid-induced urine retention develops, resolving it without interfering with pain control can be problematic.

Clinicians from Southern Illinois University School of Medicine saw a patient with a history of alcoholic cirrhosis who was hospitalized for right-sided abdominal pain, and diagnosed with portal vein thrombosis and hepatocellular cancer. The patient was treated with hydromorphone for pain and quickly developed urine retention. The patient did not respond to α-1 blockers and found a catheter to be effective but inconvenient. The clinicians gave the patient a dose of intravenous nalbuphine, an opioid used to treat moderate to severe pain that has a different mechanism of action than other opioids. The patient responded well to the medication and was able to urinate within the first 6 hours.

According to the authors, these findings suggest that clinicians should consider offering nalbuphine to patients with opioid-induced urine retention that does not respond to α-1 blockers who prefer not to continue using bladder catheterization.

Media contact: For an embargoed PDF, please contact Lauren Evans at laevans@acponline.org. To interview the lead author, Abdisamad M. Ibrahim, MD, please contact him directly at qalbinoor@gmail.com

2. Cost a key consideration of WHO guidelines for diabetes treatment intensification


Recently published guidelines make recommendations on use of medicines for treatment intensification of type 2 diabetes and type of insulin in type 1 and type 2 diabetes

Abstract: http://annals.org/aim/article/doi/10.7326/M18-1149

Editorial: http://annals.org/aim/article/doi/10.7326/M18-1148

URLs go live when the embargo lifts

The World Health Organization (WHO) recently issued guidelines on the selection of medicines for treatment intensification in patients with type 2 diabetes and on the use of insulin in patients with type 1 or 2 diabetes. A synopsis of the guidelines is published in Annals of Internal Medicine.

Type 2 diabetes is highly prevalent in most settings, and the increase in prevalence has been greatest in low- and middle-income countries in the past few decades. WHO develops guidelines for settings with limited health system resources where the health care budget can be quickly exhausted with widespread use of expensive brand-name medications. WHO guidelines also apply to high-income countries where patients with limited resources need evidence-based care that takes into account costs and value.

WHO made the following five recommendations: The authors of an accompanying commentary by members of the High Value Care Committee of the American College of Physicians (ACP) consider the nuances of clinical decision-making in the face of limited evidence and limited resources. They also compare key differences between ACP and WHO guidelines. The authors suggest that the decision to name sulfonylureas as the single best second-line agent for type 2 diabetes largely reflects the prioritization of cost and the recognition that WHO guidelines must apply to low-resource settings. ACP also acknowledges cost in its guideline, but places a priority on shared decision making between physicians and patients and on quality of life. ACP's guideline recommends that clinicians and patients discuss benefits, adverse effects, and costs when considering second-line therapy options, including sulfonylureas, which present a higher risk for hypoglycemia, and the newer agents, which may have a more favorable side-effects profile but are more expensive.

Media contact: For an embargoed PDF or to interview the editorialist from ACP's High Value Care Committee, please contact Steve Majewski at smajewski@acponline.org.

3. Patient says ALS took away control over his body; court ruling took away control over his life


Abstract: http://annals.org/aim/article/doi/10.7326/M18-1719

URLs go live when the embargo lifts

Michael Danielson (photo available), a terminally ill patient in San Diego, says that ALS took away control over his body and then the court's decision to overturn California's End of Life Option Act took away control over his life. Danielson's essay is published in Annals of Internal Medicine.

When Danielson was diagnosed with ALS, he was pragmatic about his prognosis. Knowing that the disease would eventually kill him, he told his friends and family that when the time came, he would end his life on his own terms. At the time, California was one of a handful of states that allowed physicians to legally assist patients in dying. The law was written so that a person's underlying illness and not "medical aid in dying" would be recorded as the cause of death on the death certificate. In Danielson's case, it would be ALS. This is a very important distinction for insurance companies, families, and patients going through a terminal illness.

On May 24, California's End of Life Option Act was overturned, a decision that has caused Danielson a great deal of anxiety knowing how much he will suffer. As for the Hippocratic oath doctors take that begins, 'First, do no harm,' Danielson says that doctors are doing more harm by keeping terminally ill patients alive needlessly than by allowing them to take control and have a dignified passing of their choice.

Media contact: For an embargoed PDF, please contact Lauren Evans at laevans@acponline.org. For an interview with the patient, please contact Sara Gianella Weibel at gianella@uscd.edu. To speak with Dr. David Grube from Compassion and Choices, please contact him directly at dgrube@compassionandchoices.org.
-end-
Also new in this issue:

PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation

Andrea C. Tricco, PhD, MSc; Erin Lillie, MSc; Wasifa Zarin, MPH; Kelly K. O'Brien, PhD, BScPT; Heather Colquhoun, PhD; Danielle Levac, PhD, MSc, BScPT; David Moher, PhD, MSc; Micah D.J. Peters, PhD, MA(Q); Tanya Horsley, PhD; Laura Weeks, PhD; Susanne Hempel, PhD; Elie A. Akl, MD, PhD, MPH; Christine Chang, MD, MPH; Jessie McGowan, PhD; Lesley Stewart, PhD, MSc; Lisa Hartling, PhD, MSc, BScPT

Research and Reporting Methods

Abstract: http://annals.org/aim/article/doi/10.7326/M18-0850

Scoping Reviews and Systematic Reviews: Is It an Either/Or Question?

Stephanie Chang, MD, MPH

Editorial

Abstract: http://annals.org/aim/article/doi/10.7326/M18-2205

American College of Physicians

Related Diabetes Articles from Brightsurf:

New diabetes medication reduced heart event risk in those with diabetes and kidney disease
Sotagliflozin - a type of medication known as an SGLT2 inhibitor primarily prescribed for Type 2 diabetes - reduces the risk of adverse cardiovascular events for patients with diabetes and kidney disease.

Diabetes drug boosts survival in patients with type 2 diabetes and COVID-19 pneumonia
Sitagliptin, a drug to lower blood sugar in type 2 diabetes, also improves survival in diabetic patients hospitalized with COVID-19, suggests a multicenter observational study in Italy.

Making sense of diabetes
Throughout her 38-year nursing career, Laurel Despins has progressed from a bedside nurse to a clinical nurse specialist and has worked in medical, surgical and cardiac intensive care units.

Helping teens with type 1 diabetes improve diabetes control with MyDiaText
Adolescence is a difficult period of development, made more complex for those with Type 1 diabetes mellitus (T1DM).

Diabetes-in-a-dish model uncovers new insights into the cause of type 2 diabetes
Researchers have developed a novel 'disease-in-a-dish' model to study the basic molecular factors that lead to the development of type 2 diabetes, uncovering the potential existence of major signaling defects both inside and outside of the classical insulin signaling cascade, and providing new perspectives on the mechanisms behind insulin resistance in type 2 diabetes and possibly opportunities for the development of novel therapeutics for the disease.

Tele-diabetes to manage new-onset diabetes during COVID-19 pandemic
Two new case studies highlight the use of tele-diabetes to manage new-onset type 1 diabetes in an adult and an infant during the COVID-19 pandemic.

Genetic profile may predict type 2 diabetes risk among women with gestational diabetes
Women who go on to develop type 2 diabetes after having gestational, or pregnancy-related, diabetes are more likely to have particular genetic profiles, suggests an analysis by researchers at the National Institutes of Health and other institutions.

Maternal gestational diabetes linked to diabetes in children
Children and youth of mothers who had gestational diabetes during pregnancy are at increased risk of diabetes themselves, according to new research published in CMAJ (Canadian Medical Association Journal).

Two diabetes medications don't slow progression of type 2 diabetes in youth
In youth with impaired glucose tolerance or recent-onset type 2 diabetes, neither initial treatment with long-acting insulin followed by the drug metformin, nor metformin alone preserved the body's ability to make insulin, according to results published online June 25 in Diabetes Care.

People with diabetes visit the dentist less frequently despite link between diabetes, oral health
Adults with diabetes are less likely to visit the dentist than people with prediabetes or without diabetes, finds a new study led by researchers at NYU Rory Meyers College of Nursing and East Carolina University's Brody School of Medicine.

Read More: Diabetes News and Diabetes Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.